Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Springworks therapeutics, inc. save search
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Published: 2023-05-30 (Crawled : 11:00) - biospace.com/
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -0.04%
H: 4.15%
C: 0.54%
tumors cell trial therapeutics phase 2
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Published: 2023-05-30 (Crawled : 11:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -0.04%
H: 4.15%
C: 0.54%
tumors cell trial therapeutics phase 2
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
Published: 2022-09-29 (Crawled : 11:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -0.22%
H: 0.52%
C: 0.52%
trial therapeutics phase 2
SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 0.0%
H: 3.75%
C: -3.69%
phase 2 phase 2b trial therapeutics enroll
SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-10-27 (Crawled : 11:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -0.11%
H: 8.67%
C: 7.55%
phase 2 collaboration
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 0.01%
H: 0.85%
C: -2.43%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 11.94%
H: 0.24%
C: -4.78%
phase 1 trial phase 2
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Published: 2021-06-16 (Crawled : 11:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 0.08%
H: 1.02%
C: -0.11%
phase 1 children trial phase 3 phase 2
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2021-04-12 (Crawled : 13:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -0.52%
H: 1.24%
C: -1.66%
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: 1.31%
H: 1.26%
C: -11.04%
phase 1 phase 3 phase 2
SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Published: 2021-02-25 (Crawled : 12:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -1.43%
H: 4.26%
C: -3.52%
phase 2 phase 2b trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.